Agios Pharmaceuticals (AGIO) Competitors $41.96 -0.73 (-1.71%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AGIO vs. ITCI, ROIV, ASND, RVMD, LNTH, NUVL, LEGN, BPMC, ELAN, and CYTKShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Nuvalent (NUVL), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Nuvalent Legend Biotech Blueprint Medicines Elanco Animal Health Cytokinetics Agios Pharmaceuticals (NASDAQ:AGIO) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation. Does the media prefer AGIO or ITCI? In the previous week, Agios Pharmaceuticals had 8 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 15 mentions for Agios Pharmaceuticals and 7 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.79 beat Agios Pharmaceuticals' score of 0.66 indicating that Intra-Cellular Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Intra-Cellular Therapies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is AGIO or ITCI more profitable? Agios Pharmaceuticals has a net margin of 2,051.38% compared to Intra-Cellular Therapies' net margin of -14.07%. Agios Pharmaceuticals' return on equity of -2.93% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals2,051.38% -2.93% -2.58% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has more risk & volatility, AGIO or ITCI? Agios Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Do institutionals & insiders hold more shares of AGIO or ITCI? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 4.9% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, AGIO or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Agios Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$32.87M72.80-$352.09M$11.363.69Intra-Cellular Therapies$612.78M15.04-$139.67M-$0.87-99.95 Does the MarketBeat Community favor AGIO or ITCI? Intra-Cellular Therapies received 32 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 67.84% of users gave Intra-Cellular Therapies an outperform vote while only 66.99% of users gave Agios Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAgios PharmaceuticalsOutperform Votes48966.99% Underperform Votes24133.01% Intra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% Do analysts recommend AGIO or ITCI? Agios Pharmaceuticals currently has a consensus price target of $56.33, indicating a potential upside of 34.25%. Intra-Cellular Therapies has a consensus price target of $97.23, indicating a potential upside of 11.81%. Given Agios Pharmaceuticals' higher probable upside, equities research analysts plainly believe Agios Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 SummaryAgios Pharmaceuticals and Intra-Cellular Therapies tied by winning 9 of the 18 factors compared between the two stocks. Ad Porter & CompanyForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.39B$6.83B$5.14B$9.30BDividend YieldN/A3.06%4.76%4.06%P/E Ratio3.6910.45134.4517.49Price / Sales72.80283.891,255.89139.10Price / CashN/A56.6540.5537.96Price / Book2.895.424.894.91Net Income-$352.09M$150.67M$118.26M$225.23M7 Day Performance-8.82%-5.39%14.52%-1.43%1 Month Performance-21.98%0.43%17.48%5.40%1 Year Performance80.55%16.12%35.86%22.84% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals4.3314 of 5 stars$41.96-1.7%$56.33+34.3%+80.6%$2.39B$32.87M3.69390Analyst RevisionITCIIntra-Cellular Therapies4.1678 of 5 stars$84.31+1.5%$97.23+15.3%+32.9%$8.94B$612.78M-95.91560ROIVRoivant Sciences2.667 of 5 stars$12.13+2.4%$17.93+47.8%+8.9%$8.83B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$136.47+5.1%$191.77+40.5%+16.0%$8.28B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.68-0.7%$63.67+42.5%+69.6%$7.52B$11.58M-12.54443Positive NewsLNTHLantheus4.4014 of 5 stars$94.50+1.6%$130.00+37.6%+21.9%$6.57B$1.50B15.42834Positive NewsNUVLNuvalent2.3475 of 5 stars$86.53-0.4%$112.60+30.1%+9.7%$6.15BN/A-25.0340Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.61-4.3%$81.54+142.6%-43.4%$6.14B$520.18M-36.971,800BPMCBlueprint Medicines2.9172 of 5 stars$95.54+2.5%$122.11+27.8%+9.7%$6.07B$249.38M-44.17640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.18+0.7%$16.75+37.5%-10.5%$6.02B$4.45B30.259,300CYTKCytokinetics3.9849 of 5 stars$49.20+1.1%$83.93+70.6%+32.5%$5.81B$3.22M-9.04250 Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Revolution Medicines Alternatives Lantheus Alternatives Nuvalent Alternatives Legend Biotech Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AGIO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
